Naloxon Accord (Naloxone Hydrochloride)

Naloxone Hydrochloride, the active ingredient in Naloxon Accord, is an opioid antagonist presented as a sterile injectable solution for intramuscular, intravenous use. It treats opioid overdose and reverses opioid‑induced respiratory depression in emergency settings.

GNH USA supplies Naloxon Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naloxon Accord is an opioid antagonist used in emergency medicine to counteract the effects of opioid toxicity.

- Opioid overdose: rapid reversal of life‑threatening respiratory depression. - Opioid‑induced respiratory depression: restores normal breathing function. - Acute opioid toxicity: counteracts central nervous system depression caused by opioid agonists.

Adverse reactions may occur following administration of Naloxon Accord.

Common Side Effects: - Nausea: mild to moderate feeling of queasiness. - Vomiting: occasional emesis after dose. - Sweating: increased perspiration. - Headache: transient cranial discomfort. - Agitation: restlessness or anxiety. - Elevated blood pressure: mild rise in systolic pressure.

Serious or Rare Side Effects: - Severe hypertension: marked increase in blood pressure requiring intervention. - Cardiac arrhythmia: irregular heart rhythm. - Pulmonary edema: fluid accumulation in lungs. - Anaphylaxis: severe allergic reaction with airway compromise. - Seizures: rare convulsive episodes.

Naloxon Accord should be used with careful clinical monitoring.

- Assess airway and breathing: ensure adequate ventilation before administration. - Monitor cardiovascular status: watch for hypertension or tachycardia. - Avoid in patients with known hypersensitivity to naloxone. - Use with caution in chronic opioid users: risk of acute withdrawal symptoms. - Pregnancy and lactation: limited data, weigh benefits against potential risks. - Store at ambient temperature: keep in original packaging, protect from light and moisture.

Naloxon Accord may interact with other medications that affect opioid pathways or cardiovascular function.

Major Interactions (Avoid): - Potent opioid agonists: may diminish reversal effect and require higher naloxone doses. - Mixed agonist‑antagonist opioids (e.g., buprenorphine): can precipitate severe withdrawal.

Moderate Interactions (Monitor Closely): - Monoamine oxidase inhibitors: possible hypertensive response. - Tricyclic antidepressants: may increase risk of cardiovascular effects. - Benzodiazepines: may mask opioid reversal, necessitating additional monitoring.